Resources

RESOURCES

Cardiovascular Pandemic Task Force: Webinar on Cardiovascular Research During the COVID-19 Pandemic Dates: August 20th and 21st, 2020

Session 1 – Biologic, Epidemiologic, and Clinical Considerations

1.1 Update on the current status of COVID-19 (Max O’Donnell) 1.2 Pulmonary and extrapulmonary manifestations of COVID-19 (Christina Barkauskas) 1.3 Cardiovascular and thrombotic manifestations of COVID-19 (Nir Uriel) 1.4 Racial disparities and high-risk populations (Clyde Yancy) 1.5 COVID-19 testing and assays (Tyler Brown) 1.6 Ongoing COVID-19 trials (Abhijit Duggal)

Session 2 – Clinical Trial Considerations

2.1 Key clinical research considerations during the COVID-19 pandemic: a trialist’s perspectives (Deepak Bhatt) 2.2 Rationale for integrating a COVID-19 case report form into cardiovascular research (Scott Solomon)

Session 3 – Regulatory Considerations

3.1 FDA concerns and challenges during and after the COVID-19 pandemic: Device-related perspectives (Bram Zuckerman) 3.2 FDA concerns and challenges during and after the COVID-19 pandemic: Pharma-related perspective (Norman Stockbridge)

Session 4 – Telehealth and Remote Monitoring

4.1 Telemedicine is here to stay (Jeff Wessler) 4.2 Remote patient participation is a viable solution (Jodi Akin)

Session 5 – Patient-Centered Considerations

5.1 Shared decision making challenges in the COVID-19 era (Megan Coylewright)

HVC Achievements in 2020

AR Workshop Slides

"Probability of Fatigue Fracture" Webinar

Hemo-Dur Workshop Day 1 Session 1

Hemo-Dur Workshop Day 1 Session 2

Hemo-Dur Workshop Day 2 Session 1

Hemo-Dur Workshop Day 2 Session 2